Innate Pharma (IPHA) Long-Term Investments (2017 - 2025)

Innate Pharma (IPHA) has disclosed Long-Term Investments for 6 consecutive years, with $35.8 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Long-Term Investments fell 21.46% year-over-year to $35.8 million, compared with a TTM value of $35.8 million through Dec 2022, down 21.46%, and an annual FY2022 reading of $35.8 million, down 24.08% over the prior year.
  • Long-Term Investments was $35.8 million for Q4 2022 at Innate Pharma, down from $45.6 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $46.4 million in Q4 2020 and bottomed at $35.8 million in Q4 2022.
  • Average Long-Term Investments over 5 years is $41.8 million, with a median of $41.0 million recorded in 2019.
  • The sharpest move saw Long-Term Investments tumbled 43.6% in 2018, then rose 13.33% in 2020.
  • Year by year, Long-Term Investments stood at $40.2 million in 2018, then increased by 2.0% to $41.0 million in 2019, then rose by 13.33% to $46.4 million in 2020, then fell by 1.73% to $45.6 million in 2021, then fell by 21.46% to $35.8 million in 2022.
  • Business Quant data shows Long-Term Investments for IPHA at $35.8 million in Q4 2022, $45.6 million in Q4 2021, and $46.4 million in Q4 2020.